A subsequent post hoc analysis by asthma severity revealed significant clinical benefits in actively treated subjects with moderate , persistent asthma at baseline [ 401-800g budesonide/day ( n = 175 ) ] , with greater achievement of well-controlled asthma ( 80.5 % and 66.1 % for the active treatment and placebo groups , respectively ; P = 0.021 ) and totally controlled asthma ( 54.0 % and 33.9 % , respectively , P = 0.008 ) , a higher percentage of patients with an asthma control questionnaire score < 0.75 ( 56.6 % and 40.0 % , respectively ; P = 0.039 ) and a greater mean reduction in inhaled corticosteroid use ( 218.5 g and 126.2 g , respectively ; P = 0.004 ) .